Early treatment intensification with ADT and ARPIs is now standard for mCSPC, with patient-specific factors guiding therapy selection. Enzalutamide, apalutamide, abiraterone, and darolutamide are key ...

NAI plus BCG demonstrates significant disease-specific survival, progression-free survival, and cystectomy avoidance in BCG-unresponsive high-grade papillary-only NMIBC at 36 months. The treatment is ...